HIMS Hims & Hers Health, Inc.
HIMS Hims & Hers Health, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
Desk view
Market read
Scan convergence 3 scans as of 2026-10-23 3 neutral converging
POC $28.48 · VWAP $28.04 · -1.2% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster CFO, COO + 2 others sold $2M, Sep 17–23
Coverage
9 related campaigns
HIMS Price Structure
Loading timeframes…
Peers
Every watchlist HIMS belongs to, members best 30-day change first — HIMS highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@cultural-thesis
@peptide-economy
@consumer
@insider-universe
Decision history
1 scored call · newest first · projection
How to read this: Positive 30-day excess supports an enter call. For pass, avoid, sell, or exit calls, a positive number means the name kept rising after the call.
Hims & Hers reported Q2 after Monday's close (Aug 10): a loss of $0.40 per share — wider than consensus — against revenue up 3.8% year over year, with revenue and guidance described as stronger than expected. Coverage also flags renewed legal scrutiny from an FTC lawsuit over data sharing and billing practices.
full note →Against street estimates
How HIMS's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
Recent news
Headlines about HIMS from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 14 days ago · Oct 9
- FinancialContent - Hims & Hers Health, Inc. Class A Common Stock (NYSE:HIMS) Stock Quote
- Hims & Hers Health (HIMS) Stock Price & Overview
- Hims & Hers Health, Inc. Reports Second Quarter 2026 Financial Results | Morningstar
- Hims & Hers Health, Inc. Reports Second Quarter 2026 Financial Results
- Hims Inc. - Hims & Hers Health, Inc. Reports Second Quarter 2026 Financial Results
HIMS research tape
233 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.
Desk commentary
Authored analysis and challenge notes tied to HIMS.
Obesity/GLP-1 vertical: the next-gen trade is an AI-discovery + tools barbell, not a pure drug-developer bet